Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension

por Kjeldsen, S E, Stålhammar, J, Hasvold, P, Bodegard, J, Olsson, U, Russell, D
Publicado 2010

Health-care costs of losartan and candesartan in the primary treatment of hypertension

por Henriksson, M, Russell, D, Bodegard, J, Kjeldsen, S, Hasvold, P, Stålhammar, J, Levin, L-Å
Publicado 2011

IDF2022-0622 Mortality and cardiorenal disease in type 1 and type 2 diabetes after COVID-19 and influenza hospitalization in Sweden

por Kristófl, R., Bodegard, J., Ritsinger, V., Thuresson, M., Nathanson, D., Nyström, T., Norhammar, A., Eriksson, J.W.
Publicado 2023

Diabetes and CVD risk during angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker treatment in hypertension: a study of 15 990 patients

por Hasvold, L P, Bodegård, J, Thuresson, M, Stålhammar, J, Hammar, N, Sundström, J, Russell, D, Kjeldsen, S E
Publicado 2014